Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4796821 | 0.98 | GNAI3 (0.47) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL5868698 | 0.95 | KDM1A (0.44) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL27804953 | 0.91 | GNAI3 (0.41) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL3307772 | 0.91 | GNAI3 (0.41) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL19366459 | 0.90 | KDM1A (0.44) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL1587227 | 0.89 | GNAI3 (0.38) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL2673338 | 0.89 | EPHX1 (0.44) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL20576713 | 0.86 | KCNH2 (0.59) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL17311122 | 0.86 | KCNH2 (0.59) | GNAI3GNAO1GNAI1KCNH2KDM1A | |
| SCHEMBL5868679 | 0.85 | GNAI3 (0.38) | GNAI3GNAO1GNAI1KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| CN-105492433-B | 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as PHD inhibitors | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | disclosed |
| CN-108884097-A | Pyridine derivatives, preparation method and its purposes in medicine | 浙江海正药业股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108473501-A | Therapeutic compounds, its composition and application method | 豪夫迈·罗氏有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-105492433-A | 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as PHD inhibitors | TAKEDA PHARMACEUTICALS CO | 2016-04-13 | — | — | CN | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2268631-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| EP-1737842-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100343-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | GNAI3 811/4885GNAO1 102/4885GNAI1 585/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | GNAI3 3587/4885GNAO1 4293/4885GNAI1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.